Should special precautions be taken when treating oligometastatic disease in the sacrum or pelvis with SBRT in a patient with a long life expectancy?

There's so much good data now that if you can work it out (insurance, etc) it's worth doing. My suggestion is to do it, but paint within the lines, meaning don't use a dose that's poorly studied and 1) adhere to good quality dose constraints like TG101, and 2) consider the PTV coverage...in that ord...